Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981916 | 0.90 | MAPK14 (0.45) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6983920 | 0.89 | MAPK14 (0.50) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6987129 | 0.87 | IDH1 (0.48) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6986457 | 0.86 | MAPK14 (0.54) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6981895 | 0.80 | LCK (0.53) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27581646 | 0.80 | LCK (0.53) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6987088 | 0.79 | LCK (0.53) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27581621 | 0.79 | LCK (0.53) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6986966 | 0.79 | IDH1 (0.51) | IDH1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6986129 | 0.78 | IDH1 (0.43) | IDH1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | claimed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | claimed |
| JP-2003503311-A | — | — | 2003-01-28 | — | — | JP | claimed |
| EP-1224180-A2 | SUBSTITUTED AZOLES | Novartis AG (CH) | 2002-07-24 | — | — | EP | claimed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | claimed |
| WO-2000063204-A2 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2000-10-26 | — | — | WO | claimed |
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| EP-1224180-A2 | SUBSTITUTED AZOLES | Novartis AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
| WO-2000063204-A2 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | IDH1 1556/4885MAPK14 21/4885MAPK13 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.